Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-
cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic …

Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …

Estimating progression-free survival (PFS) and overall survival superiority during clinical
trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics …

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-
common hematologic malignancy. Despite advances in therapy, MM remains largely …

Studies of survival in hematological malignancies (HMs) have generally shown an
improvement over time, although most of these studies are limited by a short follow-up …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Background Steady evolution of therapies has improved prognosis of patients with multiple
myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes …

Originally identified as a regulator of apoptosis and transcription, B‑cell lymphoma‑2‑
associated transcription factor 1 (BCLAF1) has since been shown to be associated with a …

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we
dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for …

Multiple myeloma (MM) is a currently incurable malignancy of antibody-secreting plasma
cells. Long non-coding RNAs (lncRNAs) have been recognised as an important class of …